Codexis Signs siRNA Innovator to Test ECO Synthesis Platform for Stereo-Defined Fragments
CDXS sits 50% above its 52-week low of $0.958.
Summary
Codexis has entered into an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. The collaboration will produce enzymatically synthesized oligonucleotide fragments and compare them against conventional solid-phase synthesis, evaluating purity, product quality, and ligation performance. This follows the company's first demonstration of full-length siRNA synthesis with precise stereochemical control at TIDES USA 2026. The agreement represents a commercial validation step for the ECO Synthesis platform, which Codexis is positioning as a scalable alternative to traditional oligonucleotide manufacturing. While financial terms were not disclosed, the partnership could accelerate adoption of the platform in the rapidly growing RNAi therapeutics market. Investors will look for further customer engagements and potential revenue contributions from this technology.
At the time of this announcement, CDXS was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.5M. The 52-week trading range was $0.96 to $2.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.